BridgeBio Pharma (BBIO) Asset Utilization Ratio (2021 - 2026)

BridgeBio Pharma's Asset Utilization Ratio history runs 6 years deep, the most recent figure standing at 0.5 for Q1 2026.

• In Q1 2026, Asset Utilization Ratio rose 255.33% year-over-year to 0.5; the TTM figure through Mar 2026 stood at 0.5 (up 255.33% YoY), while the FY2025 annual figure was 0.54, up 78.74% from the prior year.
• Asset Utilization Ratio came in at 0.5 for Q1 2026 at BridgeBio Pharma, down from 0.52 in the prior quarter.
• In the past five years, Asset Utilization Ratio ranged from a high of 0.52 in Q4 2025 to a low of 0.01 in Q2 2023.
• A 5-year average of 0.2 and a median of 0.14 in 2025 frame the typical range for Asset Utilization Ratio.
• Across the five-year window, Asset Utilization Ratio sank 90.41% in 2023 and jumped 2552.92% in 2024, its largest moves.
• BridgeBio Pharma's Asset Utilization Ratio stood at 0.11 in 2022, then sank by 86.52% to 0.02 in 2023, then soared by 1708.76% to 0.28 in 2024, then surged by 85.32% to 0.52 in 2025, then decreased by 3.15% to 0.5 in 2026.
• According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.5, 0.52, and 0.34 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison